Onconetix vs Yarrow Bioscience
ONCO and YARW side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ONCO and YARW compare
Yarrow Bioscience is the larger company, worth 16 times as much as Onconetix ($207M against $12.7M).
Yarrow Bioscience grew revenue faster over the last twelve months (13.8% versus −51.3% for Onconetix).
Onconetix keeps more of each dollar of sales as profit, with a net margin of −1579% compared with −4646% at Yarrow Bioscience.
Yarrow Bioscience pays a dividend yielding 112%; Onconetix does not pay one.
Yarrow Bioscience scores higher on the StockData Score (13 against 3 for Onconetix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ONCO | YARW |
|---|---|---|
| Size and price | ||
| Market cap | $12.7M | $207M |
| Share price | $3.21 | $18.03 |
| Change, 1 year | −99.8% | 2.4% |
| Change, 5 years | −100.0% | −98.1% |
| Beta (5Y) | 4.73 | 1.55 |
| Employees | 12 | 10 |
| StockData Score | ||
| Total score | 3 | 13 (better) |
| Valuation score | 1 | 1 |
| Growth score | 1 | 1 |
| Performance score | 0 | 2 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/S | 19.6× (better) | 363× |
| P/B | 0.9× | 0.8× (better) |
| FCF yield | – | −16.0% |
| Growth | ||
| Revenue growth (TTM) | −51.3% | 13.8% (better) |
| Revenue growth, 5Y average | – | −51.4% |
| Profitability | ||
| Gross margin | 80.4% | – |
| Operating margin | −2525% (better) | −5219% |
| Net margin | −1579% (better) | −4646% |
| FCF margin | – | −5811% |
| Return on equity | −105% | −16.6% (better) |
| Return on invested capital | −196% | – |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −52.4× | – |
| Current ratio | 2.21 | 42.08 (better) |
| Altman Z-score | −12.19 | 19.42 (better) |
| Piotroski F-score | 6 (better) | 3 |
| Dividends and buybacks | ||
| Dividend yield | – | 112% |
| Shareholder yield | 0.00% | 112% (better) |
| Ownership | ||
| Held by institutions | 1.7% | 2.7% |
| Held by insiders | 40.3% | 19.1% |
| Insider net buying, 12 months | $8.4K | – |
| Short interest, % of float | 40.6% | 1.5% |
Go deeper
- ONCO stock overview
- ONCO income statement
- ONCO valuation and score
- YARW stock overview
- YARW income statement
- YARW valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.